Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolae Crisan

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Journal of Cancer|December 7, 2018
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder CancerMatteo Ferro, Giuseppe Di Lorenzo, Carlo Buonerba, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Future Oncology (London, England)|July 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapyMatteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Journal of Cancer|December 7, 2018
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder CancerMatteo Ferro, Giuseppe Di Lorenzo, Carlo Buonerba, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Future Oncology (London, England)|July 19, 2021
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapyMatteo Ferro, Giuseppe Lucarelli, Ottavio de Cobelli, et al.
Pageof 9